Floatz logo

1H-Isoindol-1-one, 2,3-dihydro-2-[3-[cis-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[[(3S)-3-methyl-1-piperidinyl]methyl]-4-(trifluoromethyl)-

Malignant Pleural Mesothelioma (MPM)

Nurix Therapeutics, Inc.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

34 Active assets in the Malignant Pleural Mesothelioma (MPM) cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
AstraZeneca
Phase 2BB
Carboplatin
AstraZeneca
Phase 2BB
Pembrolizumab
NuCana plc
Phase 2B
FLUOROURACILUM
Memorial Sloan Kettering Cancer Center
Phase 2B
Atezolizumab
Swiss Cancer Institute
Phase 2B

View all 50 →

Same molecule, other indications

1H-Isoindol-1-one, 2,3-dihydro-2-[3-[cis-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[[(3S)-3-methyl-1-piperidinyl]methyl]-4-(trifluoromethyl)- is also rated in:

ovarian carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
melanomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →